Our findings should be viewed with some limitations in mind. First, it is unclear how the timing of the self-reported cannabis-related experiences relate to the period of heaviest cannabis use, limiting causal inferences that can be drawn from our data. Second, although these experiences were self-reported to have occurred “because of” one’s marijuana use, assessments were retrospective, and it is unclear how tightly these experiences were temporally linked to cannabis use. We cannot determine whether individuals were acutely intoxicated when these experiences occurred. We did not have data available on the persistence of these experiences, nor whether they were considered distressing. However, the polygenic risk for schizophrenia was associated with a greater number of cannabis-related experiences endorsed (meta-analyzed beta = 0.11, SE = 0.02, P = 1.3e−6); this provides some evidence that genetic risk for schizophrenia is associated with greater severity of cannabis-related experiences as indexed by a greater number of experiences endorsed. Third, we analyzed a variable assessing duration of daily cannabis use—self-reported the longest period of time an individual used marijuana almost every day—but this may not be
